Galapagos collaborates with Eli Lilly to develop potential new medicines for the treatment of osteoporosis
Genomics based drug discovery company Galapagos has decided to make a global collaboration with Eli Lilly to develop potential new medicines for the treatment of osteoporosis. Osteoporosis is principally a disease of middle age during which hormone levels essential for maintaining bone density decline. The development of osteoporosis is characterized by a clinically significant reduction in mean bone density due to an increase in bone resorption.
Galapagos has discovered and validated novel osteoporosis targets by using its proprietary SilenceSelect and FLeXSelect platforms, that may play a key role in bone formation. The agreement provides Lilly access to 12 of these proprietary osteoporosis targets and drug discovery programs to discover candidate drugs. Galapagos will be responsible for the development of drug candidates potentially through to phase IIa clinical Proof of Concept. Under the terms of the agreement, Lilly will have the exclusive option to further develop and commercialize these candidates on a worldwide basis. Galapagos will have the right to further develop and commercialize compounds for which Lilly does not exercise its option.
Galapagos is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.